Skip to main content

Table 1 Clinicopathological parameters according to mesothelin and CA125 expression levels

From: Co-expression of mesothelin and CA125/MUC16 is a prognostic factor for breast cancer, especially in luminal-type breast cancer patients

Parameter Total N=478 (%) Number of cases (%)
MSLN CA125 MSLN and CA125 co-expression
Positive N=75 (%) Negative N=403 (%) P-value Positive N=217 (%) Negative N=261 (%) P-value PositiveN=48 (%) Negative N=430 (%) P-value
Age, years (mean±SD)   60.3 (±11.6) 58.9 (±11.3) 0.33 57.7(±11.2) 60.2 (±11.4) 0.012 59.6(±11.6) 60.3 (±11.3) 0.90
Pathological T factor           
T1 (<2 cm) 264 31 (11.8) 233 (88.2) 0.030 125 (47.3) 139 (52.7) 0.054 19 (7.2) 245 (92.8) 0.049
T2 (2-5 cm) 194 37 (19.1) 157 (80.9)   87 (44.8) 107 (55.2)   24 (12.4) 170 (87.6)  
T3 (>5 cm) 20 7 (35.0) 13 (65.0)   5 (25.0) 15 (75.0)   5 (25.0) 15 (75.0)  
Pathological N factor           
pN1, pN2, pN3 178 29 (16.3) 149 (83.7) 0.78 79 (44.3) 99 (55.6) 0.73 23 (12.9) 155 (87.1) 0.11
pN0 300 46 (15.3) 254 (84.6)   138 (46.0) 162 (54.0)   25 (8.3) 275 (91.7)  
Pathological Stage           
0-I 201 27 (13.4) 174 (86.6) 0.13 100 (49.8) 101 (50.2) 0.26 16 (8.0) 185 (92.0) 0.12
II 221 34 (15.4) 187 (84.6)   94 (42.5) 127 (57.5)   22 (10.0) 199 (90.0)  
III 56 14 (25.0) 42 (75.0)   23 (41.1) 33 (58.9)   10 (17.9) 46 (82.1)  
Subtype           
ER/PgR+ and HER2- 333 31 (9.3) 302 (90.7) <0.0001 137 (41.1) 196 (58.9) 0.0028 17 (5.1) 316 (94.9) < 0.0001
ER/PgR+ and HER2+ 30 1 (3.3) 29 (96.7)   15 (50.0) 15 (50.0)   0 (0.0) 30 (100.0)  
HER2+ 34 7 (20.6) 27 (79.4)   16 (47.0) 18 (53.0)   4 (11.8) 30 (88.2)  
TNBC 81 36 (44.4) 45 (55.6)   49 (60.5) 32 (39.5)   27 (33.3) 54 (66.7)  
Lymphatic permeation           
Positive 284 46 (16.2) 238 (83.8) 0.71 123 (43.3) 161 (56.6) 0.27 24 (8.5) 260 (91.5) 0.16
Negative 194 29 (14.9) 165 (85.1)   94 (48.5) 100 (51.5)   24 (12.4) 170 (87.6)  
Nuclear grade           
1 117 12 (10.3) 105 (89.7) < 0.0001 55 (47.0) 62 (53.0) 0.22 7 (6.0) 110 (94.0) < 0.0001
2 140 4 (2.9) 136 (97.1)   55 (39.3) 85 (60.7)   3 (2.1) 137 (97.9)  
3 221 59 (42.1) 162 (57.9)   107 (48.4) 114 (51.6)   38 (17.2) 183 (82.8)  
Ki-67 labeling index (%)           
≥14 298 33 (11.1) 265 (88.9) 0.0004 134 (45.0) 164 (55.0) 0.81 19 (6.4) 279 (93.6) 0.0008
<14 180 42 (23.3) 138 (66.7)   83 (46.1) 97 (53.4)   29 (16.1) 151 (83.9)  
Relapse           
Yes 71 17 (23.9) 54 (76.1) 0.048 40 (56.3) 31 (43.7) 0.045 15 (21.1) 56 (78.9) 0.0022
No 407 58 (14.3) 349 (85.7)   177 (43.5) 230 (56.5)   33 (8.1) 374 (91.9)  
  1. SD standard deviation, ER Estrogen receptor, PgR Progesterone receptor, HER2 Human epidermal growth factor receptor 2, TNBC Triple-negative breast cancer, MSLN mesothelin
  2. X2 test.
  3. Values in bold are significantly different.